XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Service revenue, net $ 808 $ 316 $ 2,498 $ 935
Clinical research grants 13 9 75 9
Other 2 2 5 2
Revenue, net of contractual allowances and adjustments 823 327 2,578 946
less allowance for doubtful accounts (173) (57) (399) (168)
Net sales 650 270 2,179 778
Service revenues 653 347 1,926 813
Clinical research grants 8   65  
Total cost of sales 661 347 1,991 813
Gross (loss) profit (11) (77) 188 (35)
OPERATING EXPENSES:        
Operating expenses 2,831 2,541 7,367 3,981
Impairment of goodwill 1,275 1,015 1,569 1,015
TOTAL OPERATING EXPENSES 4,106 3,556 8,936 4,996
OPERATING LOSS (4,117) (3,633) (8,748) (5,031)
OTHER INCOME (EXPENSE):        
Interest expense, net (120) (1,883) (176) (2,265)
Warrant revaluation and modification 33   617 (3)
Derivative revaluation 117   116  
Gain on settlement liability, net 66 647 213 647
Gain (loss) on extinguishment of debt 284 (1,338) 284 (1,391)
Loss on issuance of convertible notes (112)   (1,040)  
Merger advisory fees   (73)   (2,676)
Loss on settlement of equity instrument     (385)  
Total other nonoperating income (expense) 268 (2,647) (371) (5,688)
LOSS BEFORE INCOME TAXES (3,849) (6,280) (9,119) (10,719)
INCOME TAX EXPENSE 0 0 0 0
NET LOSS (3,849) (6,280) (9,119) (10,719)
Deemed dividends related to beneficial conversion feature of preferred stock and fair value of consideration issued to induce conversion of preferred stock   (3,764) (3,848) (9,012)
Preferred dividends   (84)   (84)
TOTAL DIVIDENDS   (3,848) (3,848) (9,096)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (3,849) $ (10,128) $ (12,967) $ (19,815)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ (0.17) $ (1.36) $ (0.69) $ (6.96)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES) 23,202,208 7,430,741 18,877,601 2,846,221